First author [ref.] | Year(s) | Treatment | Bevacizumab mg·kg−1 | ORR % | PFS months | Overall survival months |
Johnson [16] | 2004 | Carboplatin+paclitaxel±bevacizumab (6 cycles) | 0 | 18.8 | 4.2 | 14.9 |
7.5 | 28.1 | 4.3 | 11.6 | |||
15 | 31.5 | 7.4 (p=0.023) | 17.7 (p=0.63) | |||
Sandler [17] | 2006 | Carboplatin+paclitaxel±bevacizumab (6 cycles) ±bevacizumab until progression | 0 | 15 | 4.5 | 10.3 |
15 | 35 (p<0.001) | 6.2 (p<0.001) | 12.3 (p=0.03) | |||
Reck [18, 19] | 2009, 2010 | Cisplatin+gemcitabine±bevacizumab (6 cycles) ±bevacizumab until progression | Placebo | 20.1 | 6.1 | 13.1 |
7.5 | 34.1 (p<0.0001) | 6.7 (p=0.003) | 13.6 (p=0.420) | |||
15 | 30.4 (p=0.0023) | 6.5 (p=0.03) | 13.4 (p=0.761) |
ORR: objective response rate; PFS: progression-free survival.